<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906734</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01-12-3.1</org_study_id>
    <nct_id>NCT03906734</nct_id>
  </id_info>
  <brief_title>Mitral Valve Management During Septal Myectomy</brief_title>
  <acronym>MVMSM</acronym>
  <official_title>Alfieri Stich Versus Secondary Cord Cutting During Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Pilot Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of the study: to evaluate whether alfieri technique improves clinical and
      hemodynamic results compared to transaortic mitral valve secondary cord cutting in patients
      scheduled to septal myectomy for severely symptomatic hypertrophic obstructive
      cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is pilot prospective randomised study comparing immediate and early results of
      additional subvalvular mitral apparatus intervention versus additional alfieri stich in
      patients scheduled to septal myectomy for symptomatic obstructive cardiomyopathy.

      Patients with proven hypertrophic cardiomyopathy and resting left ventricle outflow tract
      obstruction underwent septal myectomy. If patients were suitable for both surgical
      techniques, they were randomized to alfieri stich or secondary cord cutting. All surgeons
      were experienced at least 50 related procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2016</start_date>
  <completion_date type="Actual">March 20, 2019</completion_date>
  <primary_completion_date type="Actual">October 28, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transmitral pressure gradient</measure>
    <time_frame>30-days</time_frame>
    <description>Transmitral pressure gradient after the procedures assessed by echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repeat bypass</measure>
    <time_frame>30 day</time_frame>
    <description>Rate of second cross clamping and repeating bypass for procedure related reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual left ventricle outflow tract gradient</measure>
    <time_frame>intraoperative measuerment</time_frame>
    <description>Residual left ventricle outflow tract gradient assessed by direct measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All cause death during 30 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>alfieri technique + Septal myectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Septal myectomy plus mitral valve repair using alfieri stich</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subvalvular intervention + Septal myectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Septal myectomy plus subvalvular mitral valve intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Septal myectomy</intervention_name>
    <description>Transaortic septal myectomy</description>
    <arm_group_label>Subvalvular intervention + Septal myectomy</arm_group_label>
    <arm_group_label>alfieri technique + Septal myectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>alfieri stich</intervention_name>
    <description>Transaortic Mitral valve repair using alfieri technique</description>
    <arm_group_label>alfieri technique + Septal myectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subvalvular intervention</intervention_name>
    <description>Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release</description>
    <arm_group_label>Subvalvular intervention + Septal myectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertrophic obstructive cardiomyopathy

          -  Left ventricle outflow tract gradient &gt; 50 mm Hg at rest

          -  Systolic anterior motion mediated mitral regurgitation

        Exclusion Criteria:

          -  Intrinsic valvular heart disease

          -  Coronary artery disease

          -  Aortic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novosibirsk State Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>septal myectomy</keyword>
  <keyword>hypertrophic cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Restricted by local policy</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

